TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05267886
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline running at a standardized rate
Study: NCT04746339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice daily for 30 days
Study: NCT06254248
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:~Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept.
Study: NCT06154187
Drug: PBK_L2201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide-SC 80 μg was to be self-administered daily using a Pen Injector device.
Study: NCT06154187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was formulated similar to abaloparatide-SC.
Study: NCT04426591
Drug: Biotin Labeled Red Blood Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the day of transfusion, a 20 mL aliquot will be sterilely withdrawn from each RBC unit, washed and labeled with sulfo-NHS-biotin for 30 minutes, washed to stop the labeling reaction, then resuspended in plasma to a hematocrit of \~60%. The biotin-labeled RBC (BioRBC) will be transfused along with the remainder of the RBC unit (unlabeled volume). Standard blood bank and CTT protocols and minor antigen matching for SCD patients will be followed. Exact transfusion volume will be determined based on pre-transfusion hemoglobin (Hb), sickle cell hemoglobin (HbS), and body weight, per clinical protocol.
Study: NCT06082323
Drug: LT-002-158/Placebo oral tablet(s)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Study: NCT05227703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, oral (tablet), once per day for 6 weeks
Study: NCT05394116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
Study: NCT05176470
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06384131
Drug: ABI-4334
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg or 50 mg tablets for oral administration
Study: NCT06384131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg or 50 mg tablets for oral administration
Study: NCT05809830
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control arm in Phase II will be Doxorrubicin alone
Study: NCT05772520
Drug: TLL018 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets administered 20 mg BID and 40 mg BID for 12 weeks
Study: NCT05795816
Drug: Testofen
Normalized name: Ketofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dose of 1 capsule (300mg per capsule Testofen)
Study: NCT06210607
Drug: HS-10511 Tablets Placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10511 tablets placebo for 5\~6 SAD cohorts and 4 MAD cohorts
Study: NCT06402851
Drug: Anticoagulant Oral
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
Study: NCT06153966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching ION717 will be administered by IT injection.
Study: NCT05081245
Drug: ML-004 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo once daily.
Study: NCT04794842
Drug: Phenol 90% concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: same as information in the arm/group description
Study: NCT06533748
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT06533748
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, PO or intramuscular (IM).
Study: NCT06514963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06267001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered IV.
Study: NCT06345001
Drug: BAY3630942
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, Single administration
Study: NCT06059846
Drug: Dummy Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride administered as IV infusion.
Study: NCT06059846
Drug: Dummy Tablets
Normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBP-PI-HBr matching dummy tablets.
Study: NCT06091865
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered IV as part of chemotherapy
Study: NCT06091865
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered IV as part of chemotherapy
Study: NCT04860830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04633252
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.
Study: NCT06562985
Drug: BAY3018250 Dose 2 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection, single dose
Study: NCT06108076
Drug: Ketone Monoester (KE)
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketones are a nutritional supplement currently used by athletes for their performance enhancing effects - specifically their cardio-pulmonary benefits
Study: NCT05565820
Drug: Nix Creme Rinse Lice Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% permethrin lotion for topical application.
Study: NCT05895552
Drug: RTA 901-Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05580991
Drug: CAN1012
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN1012 IT injection (once every 4 weeks)
Study: NCT06545942
Drug: MOMA-313
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOMA-313 administered orally
Study: NCT04746924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions will consist of a sterile, normal saline solution.
Study: NCT05052255
Drug: RVU120
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
Study: NCT06358950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet containing matching placebo for once daily administration
Study: NCT06000657
Drug: Vemliver tablet
Normalized name: vetiver oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic Hepatitis B Patients Who Pretreated with Entecavir switching to Vemliver tab (Tenofovir Alafenamide Hemitartrate)
Study: NCT06665828
Drug: REGN9533
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per the protocol
Study: NCT06665828
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per the protocol.
Study: NCT06090994
Drug: Huaier granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 10g once, 3 times a day, starting within 14 days-2 months after surgery. Please refer to the medication manual for specific usage.
Study: NCT06090994
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d),day 1-14,with one course of treatment every 3 weeks, for a total of 4-6 courses.
Study: NCT05602519
Drug: propofol, rocuronium and fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: In fentanyl group (36 patients), 50 ug of fentanyl, and in oxycodone group, 4 mg of oxycodone will be administered 20 minutes before the end of the surgery, in triple blind manner.
Study: NCT05296005
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05296005
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05296005
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06149520
Drug: BAY3018250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 or dose 2 of BAY3018250
Study: NCT06149520
Drug: Placebo to BAY3018250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to BAY3018250
Study: NCT06714864
Drug: (taurolidine and heparin) catheter lock solution
Normalized name: heparin / taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: for central venous catheter instillation use
Study: NCT06714864
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Site specific standard of care
Study: NCT05627635
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05627635
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04199026
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via microdevice
Study: NCT04199026
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via microdevice
Study: NCT06265727
Drug: CRB-701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nectin-4 targeted Antibody Drug Conjugate (ADC)
Study: NCT00002005
Drug: CD4 Antigens
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06561711
Drug: Tetracycline,Metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT06561711
Drug: Minocycline,Metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT06556342
Drug: FRD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRD001 injection is a lipid-based second-generation ultrasound contrast agent. FRD001 injection in ultrasound contrast imaging could enhance the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls.
Study: NCT05037929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC placebo Q2W.
Study: NCT06454630
Drug: REGN7508
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by single intravenous (IV) dose
Study: NCT05795400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet of placebo drug dosed once daily
Study: NCT04661150
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.
Study: NCT06245083
Drug: Pyrroloquinoline quinone (PQQ)
Normalized name: pyrroloquinolinedione tricarboxylic acid
DrugBank: Pyrroloquinoline Quinone (DB03205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplement taken daily
Study: NCT05189756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated placebo capsules for optical, acoustical and haptic blinding.
Study: NCT05866861
Drug: CUG252
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUG252 will be administered by subcutaneous injection.
Study: NCT05866861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by subcutaneous injection.
Study: NCT05763576
Drug: RO7565020
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7565020 will be administered by subcutaneous injection or intravenous infusion.
Study: NCT05763576
Drug: Nucleos(t)ide analogue (NUC) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
Study: NCT06652438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: day 1- 28 per cycle
Study: NCT05626803
Drug: Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first 10 sentinel subjects will receive open label high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
Study: NCT05626803
Drug: Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 subjects will receive high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
Study: NCT05626803
Drug: Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 subjects will receive Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets; total dose is 1×10 to the power 11 IU/dose
Study: NCT05626803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 subjects will receive matching placebo
Study: NCT04849988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.
Study: NCT04717375
Drug: SAR444881
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Study: NCT05781009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04966585
Drug: Matching Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
Study: NCT04737330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
Study: NCT06036121
Drug: ADRX-0706
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody drug conjugate targeting Nectin-4
Study: NCT06026163
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base)
Study: NCT05532332
Drug: Fluoxetine 10 mg capsules
Normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
Study: NCT05532332
Drug: Prozac® 10 mg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
Study: NCT06496061
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine infusion with 0.05 mg/kg/h
Study: NCT05005637
Drug: Anti Tuberculosis Drug
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 7RH (7 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.
Study: NCT05411978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo 90 mg for 12 weeks
Study: NCT05287633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
Study: NCT05810870
Drug: MEN1611
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEN1611 is a potent, orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) with a novel structure which exhibits a strong inhibitory activity especially against the PI3K catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.
Study: NCT06177067
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
Study: NCT04745520
Drug: Analgesia
Normalized name: Analgesia Creme Rub
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
Study: NCT06099366
Drug: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate
Study: NCT06099366
Drug: Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000U/m2 Intrathecal Methotrexate
Study: NCT06099366
Drug: Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate
Study: NCT06099366
Drug: Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate
Study: NCT06099366
Drug: Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate
Study: NCT06099366
Drug: Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate
Study: NCT05402852
Drug: EuBone ® capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
Study: NCT05402852
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.
Study: NCT06099366
Drug: Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
Study: NCT06099366
Drug: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
Study: NCT06326996
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given an infusion of thiamine.
Study: NCT06326996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given an infusion of the placebo treatment.
Study: NCT05962957
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
Study: NCT06334198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally once daily in the morning.
Study: NCT05705492
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06585449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intrathecally
Study: NCT05724797
Drug: NRS-033
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of NRS-033 will be administered
Study: NCT05724797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of matching placebo will be administered
Study: NCT06431594
Drug: GSK5733584
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK5733584 will be administered
Study: NCT05633654
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets administered orally